NCT05024045 2026-03-03Study of Oral LOXO-338 in Patients With Advanced Blood CancersEli Lilly and CompanyPhase 1 Active not recruiting316 enrolled
NCT04666038 2025-04-20BRUIN CLL-321Eli Lilly and CompanyPhase 3 Active not recruiting238 enrolled 17 charts 1 FDA
NCT05172700 2024-12-18Expanded Access Program for Pirtobrutinib for Participants With B-Cell CancerEli Lilly and CompanyApproved for marketing